

Balaxi Pharmaceuticals Limited

To
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

11th February, 2022

Stock Code: **BALAXI**

Sub: Intimation under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Newspaper clippings published on 10th February, 2022, in Business Standard (English) and Nava Telangana (Regional(Telugu) Edition) regarding the un-audited Standalone and Consolidated Financial Results of the Company for the 3rd quarter and nine months ended 31st December, 2021.

The above information is also available on the website of the Company at www.balaxipharma.in

This is for your information and record.

Yours Sincerely
For Balaxi Pharmaceuticals Limited



Chinta Shalini
Company Secretary



Registered Office:

2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

Balaxi Pharmaceuticals Limited

Registered Office: 2nd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
 CIN: L25191TG1942PLC121598
 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 31/12/2021 Unaudited	Nine Months ended 31/12/2021 Unaudited	Quarter ended 31/12/2020 Unaudited	Quarter ended 31/3/2021 Unaudited	Nine Months ended 31/12/2021 Unaudited	Year ended 31/12/2021 Unaudited
1.	Total Revenue from Operations	1795.3	8064.5	2091.19	6172.36	19028.85	6599.25
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	327.58	1462.18	405.65	1297.80	3950.19	1212.47
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	327.58	1462.18	405.65	1297.80	3950.19	1212.47
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	247.39	1094.07	300.37	1217.95	3494.72	1095.17
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	247.39	1094.07	300.37	1220.73	3592.63	1092.17
6.	Paid-up Equity Share Capital (Face value of Rs. 10 each)	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year			3324.56			5497.98
8.	Earnings Per Share (of Rs.10/- each) (not annualised)						
	1. Basic (amount in Rs.)	2.47	10.94	3.00	12.18	34.95	10.95
	2. Diluted (amount in Rs.)	2.47	10.94	3.00	12.18	34.95	10.95

Notes:

- The above is an extract of the detailed format of quarter and Nine months ended 31st December, 2021 Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
- The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 9th February, 2022 and have been subjected to Limited Review by the Statutory Auditors of the Company. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited

Place: Hyderabad
 Date: 9th Feb, 2022

Ashish Maheshwari
 Managing Director



Abbott India Limited

CIN : L24239MH1944PLC007330
 Regd Office : 3, Corporate Park, Sion-Trombay Road, Mumbai - 400 071
 Tel No.: 022-5046 1000/2000/6797 8888 Fax No.: 022-5016 9400
 Email Id : investorrelations.india@abbott.com Website : www.abbott.co.in

Extract of Unaudited Financial Results for the Quarter and Nine months ended December 31, 2021

(₹ in Crores except earnings per share)

Sr. No.	Particulars	Quarter ended		Nine months ended		Year ended
		December 31, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	1,243.10	1,110.38	3,720.41	3,279.19	4,390.92
2	Net Profit for the period	266.65	237.88	787.43	724.07	925.95

